MariTide explained

MariTide, also known as maridebart cafraglutide^[1] (developmental name AMG 133), is an investigational drug developed by Amgen for the treatment of obesity. It is an agonist of the GLP-1 receptor (GLP-1R) and an antagonist of the glucose-dependent insulinotropic polypeptide receptor (GIPR). Namely, MariTide consists of a monoclonal antibody against GIPR conjugated to two peptidic GLP-1R agonist molecules via amino acid linkers.^[2] In a preliminary trial, AMG 133 resulted in a 14.5 percent weight loss after 12 weeks at the highest dose tested.^{[3] [4] [5]}

Notes and References

1. Web site: Beasley . Deena . Amgen taking different path to weight loss windfall . Reuters . 2024-02-06 . 2024-03-06.
2. Véniant . Murielle M. . Lu . Shu-Chen . Atangan . Larissa . Komorowski . Renee . Stanislaus . Shanaka . Cheng . Yuan . Wu . Bin . Falsey . James R. . Hager . Todd . Thomas . Veena A. . Ambhaikar . Malhar . Sharpsten . Lucie . Zhu . Yineng . Kurra . Vamsi . Jeswani . Rohini . 2024-02-05 . A GIPR antagonist conjugated to GLP-1 analogues promotes weight loss with improved metabolic parameters in preclinical and phase 1 settings . Nature Metabolism . en . 6 . 2 . 290–303 . 10.1038/s42255-023-00966-w . 2522-5812 . 10896721 . 38316982.
3. Hammoud . Rola . Drucker . Daniel J. . Beyond the pancreas: contrasting cardiometabolic actions of GIP and GLP1 . Nature Reviews Endocrinology . April 2023 . 19 . 4 . 201–216 . 10.1038/s41574-022-00783-3 . en . 1759-5037.
4. Jepsen . Mathies M. . Christensen . Mikkel B. . Emerging glucagon-like peptide 1 receptor agonists for the treatment of obesity . Expert Opinion on Emerging Drugs . 3 July 2021 . 26 . 3 . 231–243 . 10.1080/14728214.2021.1947240.
5. Bailey . Clifford J. . Flatt . Peter R. . Conlon . J. Michael . An update on peptide-based therapies for type 2 diabetes and obesity . Peptides . 1 March 2023 . 161 . 170939 . 10.1016/j.peptides.2023.170939 . 0196-9781. free .